MOUNTAIN VIEW, Calif., May 5, 2010 /PRNewswire via COMTEX/ -- VIVUS, Inc. /quotes/comstock/15*!vvus/quotes/nls/vvus (VVUS 11.89, -0.12, -0.10%) today announced that new data on Qnexa(R), an investigational drug candidate, will be presented at EuroPRevent 2010, the annual congress of the European Association for Cardiovascular Prevention and Rehabilitation, organized by the European Society of Cardiology, in Prague, Czech Republic. Kishore Gadde, MD, director of obesity clinical trials at Duke University and a lead investigator, will make two presentations based on the results of the CONQUER (OB-303) study, which studied the effects of Qnexa on overweight or obese patients with two or more co-morbidities over 56 weeks. On May 6, Dr. Gadde will make a poster presentation entitled, "12-Month Weight Loss and Antihypertensive Benefits With PHEN/TPM CR in Overweight and Obese Subjects With Hypertension," followed by a moderated poster presentation on May 7 entitled, "12-Month Weight Loss and Triglyceride Changes With PHEN/TPM CR in Overweight and Obese Subjects With Hypertriglyceridemia."
"We are thrilled to be sharing the Qnexa hypertension and lipid clinical data with our medical and industry colleagues in Europe at this prestigious congress," stated Peter Tam, president, VIVUS. "Earlier in the week, Dr. Oparil shared the pooled antihypertensive 28-week Qnexa data with her cardiology colleagues at the American Society of Hypertension. Dr. Gadde's presentations at EuroPRevent 2010 will feature data highlighting the effects of Qnexa on weight-related co-morbidities with our colleagues in Europe. We look forward to being a part of this and other key clinical meetings." |
Thread abonnieren
